Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 4/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.39 |
| ▸ | CDK9 | P50750 | 10/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 9/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5020053 | 0.92 | GRM2 (0.43) | GRM2SLC6A3 | |
| SCHEMBL4566385 | 0.85 | GRM2 (0.50) | GRM2 | |
| SCHEMBL5020035 | 0.84 | GRM2 (0.41) | GRM2 | |
| SCHEMBL5020038 | 0.81 | GRM2 (0.54) | GRM2SLC6A3NTSR1CDK9CCNT1 | |
| SCHEMBL16755854 | 0.81 | GRM2 (0.56) | GRM2SLC6A3 | |
| SCHEMBL5020036 | 0.78 | GRM2 (0.58) | GRM2SLC6A3NTSR1CDK9CCNT1 | |
| SCHEMBL16755911 | 0.77 | GRM2 (0.52) | GRM2 | |
| SCHEMBL16755876 | 0.76 | CHRM4 (0.41) | GRM2CHRM4CHRM2 | |
| SCHEMBL16755901 | 0.76 | GRM2 (0.56) | GRM2 | |
| SCHEMBL16755836 | 0.74 | GRM2 (0.56) | GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2638040-A1 | RADIOLABELLED mGLuR2 PET LIGANDS | Janssen Pharmaceuticals, Inc. (US) | 2013-09-18 | — | — | EP | disclosed |
| US-20130230459-A1 | RADIOLABELLED mGluR2 PET LIGANDS | Janssen Pharmaceuticals, Inc. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130230459-A1 | RADIOLABELLED mGluR2 PET LIGANDS | Janssen Pharmaceuticals, Inc. (US) | 2013-09-05 | — | — | US | disclosed |
| WO-2012062752-A1 | RADIOLABELLED mGLuR2 PET LIGANDS | Janssen Pharmaceuticals, Inc. (US) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130230459-A1 | RADIOLABELLED mGluR2 PET LIGANDS | GRM2, GRM3, GRM1 | GRM2 1/4885SLC6A3 310/4885NTSR1 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.